As sustainability pressures drive innovation in pressurised Metered Dose Inhalers (pMDIs), the regulatory landscape must shift to accommodate new low carbon technology. In a sector that has already undergone one major transition in recent decades, how are regulators, drug developers and contract development and manufacturing organisations (CDMOs) responding?
In our article with IPI (International Pharmaceutical Industry), Sarah Bunyan, Head of Regulatory Affairs at Bespak, explores key considerations in this space.
